Condition
Alpha-Thalassemia
Total Trials
6
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Recruiting3
Completed2
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05687474Completed
Baby Detect : Genomic Newborn Screening
NCT04872179RecruitingPrimary
International Registry of Patients With Alpha Thalassemia
NCT06831799Completed
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
NCT06539169RecruitingPrimary
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
NCT06591936RecruitingPrimary
Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .
NCT01419704Phase 1Withdrawn
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
Showing all 6 trials